TCG Crossover Management’s Elevation Oncology ELEV Stock Holding History

TCG Crossover Management’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-288,390	Closed	-$274K	–	23
2022 Q4	$274K	Sell	288,390 -266,610	-48%	-$271K	0.05%	21
2022 Q3	$627K	Hold	555,000	–	–	0.19%	21
2022 Q2	$777K	Hold	555,000	–	–	0.33%	21
2022 Q1	$1.4M	Hold	555,000	–	–	0.56%	20
2021 Q4	$3.34M	Buy	+555,000	New	+$3.83M	1.56%	15

Other funds holding ELEV

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Walleye Capital

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return